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PERSPECTIVE
DJ-1 as a deglycating enzyme: a unique 
function to explain a multifaceted 
protein?
The Parkinson’s disease (PD)-associated protein DJ-1 is considered 
a multifunctional protein involved in oxidative stress responses. 
Although a large variety of functions has been attributed to DJ-
1, currently no consensus has been found on its effective cellular 
activity. Indeed, the protein has been described as a transcriptional 
modulator, a regulator of mitochondrial activity, a stabilizer of the 
nuclear factor erythroid 2-related factor (Nrf2), a chaperone, a pro-
tease, and a glutathione (GSH)-independent glyoxalase (Ariga et al., 
2013). Very recently, the additional participation of the protein to 
carbonyl stress defense has been emerging (Richarme et al., 2015). 
Carbonyl stress is a harmful condition characterized by an excessive 
amount of reactive carbonyl species with glycating potential. These 
compounds are unavoidable intermediates of metabolic pathways 
and are characterized by a high level of reactivity towards nucleop-
hilic molecules. Carbonyl attack principally involves biomolecules 
such as proteins, nucleic acids, and phospholipids, causing cyto-
toxicity and genotoxicity. Although glucose is the most abundant 
glycating agent, methylglyoxal (MGO) and glyoxal (GO) are consid-
ered the principal glycating players because of their high reactivity. 
These species, generated as by-products of the glycolytic flux, are 
capable of reacting with biological molecules affecting their stability 
and functions. In particular, these compounds can react with argi-
nine and lysine residues of proteins and with guanosine and deox-
yguanosine nucleotides (Thornalley, 2008). Spontaneous glycation 
promotes the reversible formation of an unstable Schiff base that 
undergoes a rearrangement into a more stable ketoamine, named 
Amadori product. This molecule can further rearrange to even-
tually yield irreversible advanced glycation end products (AGEs), 
which have been associated with diabetes and several age-related 
diseases (Thornalley, 2008). To counteract these dangerous mod-
ifications, cells have developed different protective mechanisms, 
which include aldoketoreductases that convert carbonyls into alco-
hols, glyoxalases that degrade methylglyoxal and glyoxal releasing 
lactate and glycolate, respectively, and fructosamine-3-kinases that 
phosphorylates lysine-fructosamines generated after glucose glyca-
tion (Richarme et al., 2015). In this regard, the activity of DJ-1 as a 
deglycating enzyme recently reported by Richarme and co-workers 
is of particular interest. The investigators have shown, in vitro, that 
DJ-1 is able to restore damaged proteins, preventing Schiff base for-
mation. Specifically, DJ-1 has been demonstrated to restore glycated 
N-acetylcysteine, N-acetylarginine and N-acetylysine amino acids 
after their reaction with MGO. Moreover, this function has been 
confirmed using different glycated proteins, including bovine se-
rum albumin, glyceraldehyde 3-phosphate dehydrogenase, aldolase, 
fructose-1,6-biphosphate, and aspartate transaminase. Interestingly, 
this activity seems to be dependent on a highly-conserved cysteine 
residue located at position 106, whose mutation has been shown 
to impair DJ-1-dependent deglycation. Noteworthy, this function 
seems to be exerted during early glycating events, before AGEs 
formation. Indeed, using bovine serum albumin as glycation target, 
the authors have shown that, once the Schiff base is formed, DJ-1 
cannot deglycate it, while it acts on aminocarbinol, the Schiff base 
precursor (Richarme et al., 2015). Besides acting on glycated pro-
teins, the same group has reported, very recently, that DJ-1 is able to 
prevent nucleic acids glycation by performing the so-called “nucle-
otide sanitization” (Richarme et al., 2017). Similarly to the protein 
related process, DJ-1 has been described to work only on early steps 
of the glycation reaction. Moreover, the C106S DJ-1 mutant does 
not present deglycating activity, further confirming that this residue 
is required for its protective function against carbonyl stress. 
As emphasized by Richarme and colleagues, this new function 
could reconcile some of the previously described activities at-
tributed to DJ-1 (Richarme et al., 2015). Indeed, to perform its 
deglycase activity, DJ-1 acts as: (i) a chaperone to interact with 
glycated molecules; (ii) a glyoxalase 1 to transform hemithioacetals 
into thioesters and aminocarbinols into amides; (iii) a glyoxalase 
2 to cut thioesters for cysteine deglycation; and (iv) a protease to 
break amide bonds favoring lysine/arginine deglycation (Richarme 
et al., 2015). Moreover, this function may contribute to justify the 
multifarious subcellular localization described for DJ-1. Indeed, the 
protein is mainly cytosolic but it has been also detected at the nu-
clear and mitochondrial level (Ariga et al., 2013). These subcellular 
localizations may reflect the different compartments in which the 
protein exerts its deglycating function, acting on both proteins and 
nucleic acids. Very interestingly, the deglycating activity attributed 
to DJ-1 might also explain the participation of the protein in tumor 
growth. Experimental evidence supports the overexpression of DJ-1 
in many tumor types, such as prostate cancer, ovarian carcinoma, 
breast cancer, and acute leukemia (Cao et al., 2015). Indeed, DJ-1 
has been shown to stimulate cell proliferation and to repress apop-
tosis, two key events that are often dysregulated in tumors (Cao et 
al., 2015). For example, DJ-1 has been suggested to favor survival by 
stimulating the protein kinase B (PKB/Akt) pathway and inhibiting 
its repressor, the phosphatase and tensin homolog deleted on chro-
mosome 10 (PTEN), a known tumor suppressor (Cao et al., 2015). 
In this contest, the emerging role of DJ-1 as a novel deglycase may 
represent a different mechanism through which the protein could 
promote tumor growth. Actually, malignant tumors are charac-
terized by high levels of glycolysis, the so-called “Warburg Effect”, 
and the enhanced glycolytic flux could make DNA, proteins and 
lipids more susceptible to glycation than normal cells. Nonetheless, 
since DJ-1 is highly expressed in tumor cells too, its function as a 
deglycase could represent a mechanism to preserve malignant cells 
integrity, thus favoring their sustained proliferation. 
Another aspect that could be explained by the new activity as-
sociated with DJ-1 is the recently described connection between 
diabetes and PD. If on one hand diabetes represents a risk factor 
for PD development (Yang et al., 2017), on the other hand, more 
than 60% of the PD patients present an impairment in the insu-
lin signaling and are glucose intolerant (Santiago and Potashkin, 
2013). In this frame, the recent involvement of DJ-1 in diabetes is 
worthy of note. Indeed, Jain and colleagues have found that DJ-1 
is down-regulated in pancreatic islets of type II diabetes mellitus 
patients, while in non-diabetic individuals, its expression increases 
with aging (Jain et al., 2012). Furthermore, the investigators report-
ed that DJ-1-deficient aged mice develop glucose intolerance and a 
reduced β-cell area (Jain et al., 2012). Therefore, DJ-1 is not only a 
recognized PD-associated protein, but it also might participate to 
glucose homeostasis and diabetes onset, and the recent discovery of 
DJ-1 as a novel deglycase could help to understand its involvement 
in diabetes and post-diabetic diseases. As a matter of fact, glycation 
has been reported to favor diabetes complications, including ath-
erosclerosis, hypertension, nephropathy, cataracts, retinopathy, and 
cardiomyopathy. Therefore, the deglycating function of DJ-1 might 
represent a protective mechanism to limit glycation side effects and 
the development of diabetic complications. 
The results concerning the deglycase activity of DJ-1 appear com-
pelling even though further experiments are required to confirm 
this novel role associated with the protein. Specifically, in vivo data 
are highly awaited to assess whether the deglycase activity occurs 
under physiological conditions. Actually, besides biochemical 
assays, the activity has been demonstrated only in bacteria and hu-
man-derived cell cultures (Abdallah et al., 2016; Advedissian et al., 
2016). Indeed, authors utilized Escherichia coli mutants for DJ-1 
homologues, named hchA, yhbO, and yajL, showing that they have 
higher glycation content at DNA and RNA levels compared to wild 
type strains. Furthermore, triple mutants for DJ-1 homologues have 
2.5 times more glycation level than mutants for proteins belonging 
to the system of glycated DNA repair, suggesting that the bacterial 
DJ-1 homologues play an important role in glycated DNA repair 
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(Richarme et al., 2017). Consistent with these results, Advedissian 
and colleagues have showed that cultured human keratinocytes, 
in which DJ-1 has been silenced by siRNA, are characterized by 
increased glycation, while the overexpression of DJ-1 promotes a 
reduction of AGEs level (Advedissian et al., 2016). It is worth men-
tioning that some contrasting findings have been also reported. 
Indeed, Pfaff and co-workers were not able to observe any deglycat-
ing activity, in vitro, using both human DJ-1 and D. melanogaster 
homologue DJ-1β. Moreover, they did not reveal accumulation of 
glycated proteins in their DJ-1β null fly model compared to wild-
type flies, suggesting that DJ-1β might not participate in protein de-
glycation (Pfaff et al., 2017). In the light of these findings, to better 
characterize this function in vivo, future experiments should be per-
formed using mammalian model organisms, in which there is only 
one single DJ-1 homologue, differently from bacteria and flies. For 
example, under DJ-1 depletion, it would be expected that mammals 
present a higher accumulation of glycated biomolecules, while, on 
the other hand, its overexpression should reduce carbonyl damages. 
To address this point, the discovery that some small molecules are 
able to increase the levels of DJ-1 can be very useful. For instance, 
Zhou et al. (2011) have reported that phenylbutyrate, a histone 
deacetylase inhibitor, is able to enhance DJ-1 expression, in vivo, 
promoting protection to dopaminergic neurons against 1-meth-
yl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxin. In contrast, 
in DJ-1 knockout mice, the same compound did not more explicate 
any protective function, indicating that its action is dependent on 
the presence of DJ-1. Therefore, phenylbutyrate might represent a 
suitable molecule to up-regulate the DJ-1 expression in vivo, allow-
ing the investigation of its deglycase activity. Another compound, 
which has been described to enhance the expression of DJ-1, is the 
isothiocyanate sulforaphane, extracted from cruciferous vegeta-
bles (Advedissian et al., 2016). Specifically, this molecule has been 
demonstrated to stimulate the expression of protective enzymes, 
among which DJ-1, and to decreased protein glycation in HaCaT 
keratinocytes (Advedissian et al., 2016). Conjointly to experiments 
in animal models, it would be interesting to evaluate whether PD 
patients with DJ-1 mutations present higher glycation level and are 
more prone to develop diabetes. 
To summarize, as represented in Figure 1, the proposed degly-
case activity of DJ-1 could explain several features that have been 
attributed to the protein so far. Moreover, a great novelty of these 
findings is that DJ-1 may represent the first identified enzyme able 
to restore both proteins and nucleic acids after glycation damag-
es, since no other protein has been yet identified with this ability. 
Although this activity requires further confirmations, especially 
in vivo, the recent discoveries discussed here might shed light on 
a novel aspect of the physiological function of DJ-1, attempting to 
clarify the multifaceted nature of this protein.
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Figure 1 The recently reported deglycating activity of DJ-1 reconciles 
several features previously described for the protein. 
The deglycating activity reported for DJ-1 may explain its different 
subcellular localizations, indeed the protein has been found in the cy-
toplasm, nucleus, and mitochondria. Moreover, this proposed activity 
could help to understand the involvement of the protein in Parkinson’s 
disease (PD), tumor growth and diabetes. 
